A detailed history of Ubs Group Ag transactions in Greenwich Life Sciences, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 1,807 shares of GLSI stock, worth $24,286. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,807
Previous 402 349.5%
Holding current value
$24,286
Previous $8,000 287.5%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$12.07 - $19.04 $16,958 - $26,751
1,405 Added 349.5%
1,807 $31,000
Q1 2024

May 13, 2024

SELL
$8.31 - $20.32 $11,949 - $29,220
-1,438 Reduced 78.15%
402 $8,000
Q4 2023

Feb 09, 2024

BUY
$7.77 - $12.3 $14,289 - $22,619
1,839 Added 183900.0%
1,840 $19,000
Q3 2023

Nov 09, 2023

SELL
$8.41 - $10.66 $1,909 - $2,419
-227 Reduced 99.56%
1 $0
Q2 2023

Aug 11, 2023

BUY
$9.58 - $13.2 $2,174 - $2,996
227 Added 22700.0%
228 $2,000
Q1 2023

May 12, 2023

SELL
$12.12 - $20.8 $8,762 - $15,038
-723 Reduced 99.86%
1 $0
Q4 2022

Feb 08, 2023

SELL
$9.04 - $16.88 $9,808 - $18,314
-1,085 Reduced 59.98%
724 $11,000
Q3 2022

Nov 10, 2022

BUY
$7.81 - $12.02 $7,333 - $11,286
939 Added 107.93%
1,809 $17,000
Q2 2022

Aug 10, 2022

BUY
$7.14 - $20.36 $321 - $916
45 Added 5.45%
870 $7,000
Q1 2022

May 16, 2022

SELL
$16.3 - $24.65 $31,605 - $47,796
-1,939 Reduced 70.15%
825 $16,000
Q4 2021

Feb 14, 2022

SELL
$21.76 - $39.43 $33,640 - $60,958
-1,546 Reduced 35.87%
2,764 $67,000
Q3 2021

Nov 15, 2021

BUY
$38.65 - $46.11 $137,207 - $163,690
3,550 Added 467.11%
4,310 $168,000
Q2 2021

Aug 13, 2021

BUY
$31.24 - $53.6 $14,089 - $24,173
451 Added 145.95%
760 $34,000
Q1 2021

May 12, 2021

SELL
$22.37 - $39.98 $12,773 - $22,828
-571 Reduced 64.89%
309 $11,000
Q4 2020

Feb 11, 2021

BUY
$3.48 - $72.22 $2,098 - $43,548
603 Added 217.69%
880 $32,000
Q3 2020

Nov 12, 2020

BUY
$4.6 - $5.0 $1,274 - $1,385
277 New
277 $1,000

Others Institutions Holding GLSI

About Greenwich LifeSciences, Inc.


  • Ticker GLSI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,848,200
  • Market Cap $173M
  • Description
  • Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who ha...
More about GLSI
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.